EyeGate Issued New P
EyeGate Issued New Patent for Iontophoretic Contact Lens Technology
11 avr. 2018 08h30 HE | EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., April 11, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Receives FDA
EyeGate Receives FDA Feedback on Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel
09 avr. 2018 08h30 HE | EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., April 09, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Completes En
EyeGate Completes Enrollment and Receives Milestone Payment for Confirmatory Phase 3 Clinical Study of EGP-437 in Anterior Uveitis
06 avr. 2018 08h30 HE | EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., April 06, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), today announced completion of patient enrollment for the pivotal Phase 3...
EyeGate Pharma To Pa
EyeGate Pharma To Participate At The 30TH Annual ROTH Conference
09 mars 2018 08h30 HE | EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., March 09, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Pharma Submi
EyeGate Pharma Submits Investigational Device Exemption Amendment for Second Pilot Study of Ocular Bandage Gel
08 mars 2018 08h30 HE | EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary...
EyeGate Pharmaceutic
EyeGate Pharmaceuticals Reports Full-Year 2017 Financial Results and Provides Business Update
02 mars 2018 16h28 HE | EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., March 02, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...